RU2016134905A - Композиция для ускорения проникновения через кожу, препарат для трансдермального введения и препарат трансдермального пластыря - Google Patents

Композиция для ускорения проникновения через кожу, препарат для трансдермального введения и препарат трансдермального пластыря Download PDF

Info

Publication number
RU2016134905A
RU2016134905A RU2016134905A RU2016134905A RU2016134905A RU 2016134905 A RU2016134905 A RU 2016134905A RU 2016134905 A RU2016134905 A RU 2016134905A RU 2016134905 A RU2016134905 A RU 2016134905A RU 2016134905 A RU2016134905 A RU 2016134905A
Authority
RU
Russia
Prior art keywords
drug
composition
skin
accelerating
transdermal
Prior art date
Application number
RU2016134905A
Other languages
English (en)
Inventor
Йосики МАЕДА
Киохей МАЦУСИТА
Вэньцзин ЛИ
Кацуюки ОКУБО
Мицухико ХОРИ
Original Assignee
Нитто Денко Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Нитто Денко Корпорейшн filed Critical Нитто Денко Корпорейшн
Publication of RU2016134905A publication Critical patent/RU2016134905A/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/366Lactones having six-membered rings, e.g. delta-lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • A61K31/612Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (16)

1. Композиция для ускорения проникновения через кожу, которая содержит
соединение флавоноида,
при этом композиция используется для ускорения проникновения лекарственного средства через кожу.
2. Композиция для ускорения проникновения через кожу по п. 1,
в которой соединение флавоноида представляет собой соединение, которое имеет флавоновый скелет, представленный формулой (1)
Figure 00000001
.
3. Композиция для ускорения проникновения через кожу по п. 2,
в которой соединение, которое имеет флавоновый скелет, представленный формулой (1), представляет собой по меньшей мере одно соединение, выбранное из группы, состоящей из кверцетина, апигенина и мирицетина.
4. Препарат для трансдермального введения, который содержит
лекарственное средство; и
композицию для ускорения проникновения через кожу по п. 1, 2 или 3.
5. Препарат пластыря, который содержит
содержащий лекарственное средство слой, который содержит лекарственное средство и композицию для ускорения проникновения через кожу по п. 1, 2 или 3.
6. Препарат пластыря по п. 5,
в котором содержащий лекарственное средство слой представляет собой содержащий лекарственное средство адгезивный слой, и
содержащий лекарственное средство адгезивный слой предоставлен на одной поверхности основы.
RU2016134905A 2014-01-29 2015-01-28 Композиция для ускорения проникновения через кожу, препарат для трансдермального введения и препарат трансдермального пластыря RU2016134905A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014-014539 2014-01-29
JP2014014539 2014-01-29
PCT/JP2015/052388 WO2015115495A1 (ja) 2014-01-29 2015-01-28 皮膚透過促進組成物、経皮投与製剤及び貼付製剤

Publications (1)

Publication Number Publication Date
RU2016134905A true RU2016134905A (ru) 2018-03-05

Family

ID=53757068

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016134905A RU2016134905A (ru) 2014-01-29 2015-01-28 Композиция для ускорения проникновения через кожу, препарат для трансдермального введения и препарат трансдермального пластыря

Country Status (9)

Country Link
US (1) US20170000751A1 (ru)
EP (1) EP3100744A4 (ru)
JP (1) JP2015163606A (ru)
KR (1) KR20160106761A (ru)
CN (1) CN105939729A (ru)
BR (1) BR112016017496A2 (ru)
CA (1) CA2937526A1 (ru)
RU (1) RU2016134905A (ru)
WO (1) WO2015115495A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105380929A (zh) * 2015-11-23 2016-03-09 蚌埠丰原涂山制药有限公司 一种含洛索洛芬钠的药物组合物及其制备方法
KR102081217B1 (ko) * 2017-09-13 2020-02-25 연세대학교 산학협력단 네프린 억제제를 유효성분으로 포함하는 피부 투과 촉진용 조성물
CN111135087A (zh) * 2020-01-09 2020-05-12 范小玲 一种溶剂型透皮贴的工业化制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5936611A (ja) * 1982-08-26 1984-02-28 Nitto Electric Ind Co Ltd 粘着性貼付製剤
JPS5955822A (ja) * 1982-09-24 1984-03-31 Nitto Electric Ind Co Ltd 粘着性貼付製剤用膏体
JPS6137304A (ja) 1984-07-31 1986-02-22 Nippon Steel Corp 傾斜ロ−ル圧延機
JPH0429934A (ja) * 1990-05-28 1992-01-31 Seiichi Umeda いちょう葉抽出エキスを含有する外用組成物
JPH10139690A (ja) * 1996-11-02 1998-05-26 Shinichi Konuma 経皮吸収促進剤
JP4073517B2 (ja) 1997-04-07 2008-04-09 久光製薬株式会社 経皮吸収貼付剤用粘着剤及び経皮吸収貼付剤
US20030175333A1 (en) * 2002-03-06 2003-09-18 Adi Shefer Invisible patch for the controlled delivery of cosmetic, dermatological, and pharmaceutical active ingredients onto the skin
US7241456B2 (en) * 2002-10-25 2007-07-10 Australian Importers Ltd. Formulations for topical delivery of bioactive substances and methods for their use
JP4027850B2 (ja) * 2003-06-20 2007-12-26 ポーラ化成工業株式会社 経皮吸収促進化粧料
US8016811B2 (en) 2003-10-24 2011-09-13 Altea Therapeutics Corporation Method for transdermal delivery of permeant substances
EP1867323A1 (en) * 2006-06-13 2007-12-19 Farmatron Ltd. Pharmaceutical compositions with biological barriers permeation enhancing properties
US20100048628A1 (en) * 2006-12-01 2010-02-25 Sumiyo Nishi Method for suppressing discoloration over time of adhesive preparation containing donepezil
JP5224770B2 (ja) 2007-03-19 2013-07-03 金印株式会社 コラーゲン産生促進剤、促進方法、香粧品、飲食品および医薬品
MX338211B (es) * 2009-10-22 2016-03-30 Api Genesis Llc Metodos para hacer y utilizar composiciones que comprenden flavonoides.
EP2629763B1 (en) * 2010-10-22 2017-12-06 Vizuri Health Sciences LLC Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
JP2012206979A (ja) 2011-03-30 2012-10-25 Ssp Co Ltd 経皮投与用医薬組成物
JP5856424B2 (ja) 2011-10-05 2016-02-09 祐徳薬品工業株式会社 ロチゴチン含有経皮吸収型貼付剤

Also Published As

Publication number Publication date
CA2937526A1 (en) 2015-08-06
WO2015115495A1 (ja) 2015-08-06
JP2015163606A (ja) 2015-09-10
US20170000751A1 (en) 2017-01-05
EP3100744A1 (en) 2016-12-07
EP3100744A4 (en) 2017-08-30
KR20160106761A (ko) 2016-09-12
CN105939729A (zh) 2016-09-14
BR112016017496A2 (pt) 2017-08-08

Similar Documents

Publication Publication Date Title
BR112018068748A2 (pt) composto, composição farmacêutica e de vacina, métodos para indução ou promoção de uma resposta imunológica, para tratamento de câncer, de doenças infecciosas, de distúrbios imunológicos e de doenças imunológicas e para tratamento ou prevenção de uma doença, e, uso de um composto
BR112015011112A2 (pt) composto oligomérico, oligômero, composição farmacêutica, uso do composto oligomérico, método de síntese de um composto oligomérico e método de tratamento de uma doença.
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
CO2018008421A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CL2015001756A1 (es) Compuestos derivados de carbamoilpiridona policiclicos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion de vih en un humano que tiene o se encuentra en riesgo de tener la infeccion.
CL2013002414A1 (es) Compuestos derivados de azabencimidazol ciclico, activadores de la proteina cinasa activada por amp; composicion farmaceutica que los comprende; y su uso para el tratamiento o enfermedad tal como diabetes tipo 2, hiperglicemia, sindrome metabolico, obesidad, hipercolesterolemia e hipertension.
BR112017005393A2 (pt) composto de fórmula i, método de preparação de um conjugado de fórmula a, conjugado de fórmula a1, composição compreendendo uma mistura dos compostos de conjugado de anticorpo-fármaco, composição farmacêutica, e uso de um conjugado ou de uma composição
UY36340A (es) Derivados de indoles mono- o disustituidos como inhibidores de la replicación del virus del dengue
CL2013001339A1 (es) Compuestos derivados heterociclicos condensados, con actividad antiviral; composicion farmaceutica que los comprende; y su uso para la prevencion o tratamiento de la infeccion de vih.
CL2013001141A1 (es) Compuestos derivados de heterociclos condensados, inhibidores del virus de la hepatitis c; composicion farmaceutica que los contiene; y su uso para el tratamiento de la infeccion por el virus de la hepatitis c.
TR201908994T4 (tr) Farmasötik bileşimler.
DOP2016000226A (es) Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
AR088622A1 (es) 18-METIL-6,7-METILEN-3-OXO-17-PREGN-4-EN-21,17b-CARBOLACTONA, PREPARADOS FARMACEUTICOS QUE CONTIENEN LOS COMPUESTOS MENCIONADOS Y SU USO EN LA TERAPIA DE LA ENDOMETRIOSIS
CL2014000393A1 (es) Compuestos derivados de benzofurano y sus sales, como inhibidores del virus de hepatitis c; composicion farmaceutica que los comprende; y su uso para el tratamiento o la prevencion de una infeccion por el virus de hepatitis c o de una enfermedad asociada con dicha infeccion.
CU20140037A7 (es) Derivados de estra- 1,3,5(10), 16- tetraen- 3- carboximida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
CL2014003012A1 (es) Formulación en capsulas que comprende al menos un compuesto de formula (i), solubilizado; metodo de administracion de la formulacion; uso para tratar una infeccion por el virus de la hepatitis c.
ECSP17059323A (es) Formulacion de combinacion de tesofensina y betabloqueante
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
DK3168214T3 (da) Substituerede 2-thioxo-imidazolidin-4-oner og spiro- analoger deraf, aktiv anti-canceringrediens, farmaceutisk sammensætning, medicinpræparat, fremgangsmåde til behandling af prostatacancer
EA201890532A1 (ru) Новые аннелированные бензамиды
BR112017004000A2 (pt) formas cristalinas de 6-((6,7-dimetoxiquinazolin-4-il)óxi)-n,2-dimetilbenzofuran-3-carboxamida
RU2016134905A (ru) Композиция для ускорения проникновения через кожу, препарат для трансдермального введения и препарат трансдермального пластыря
CL2014003607A1 (es) Compuestos derivados de benzodioxol, inhibidores de la acetilcolinesterasa; metodo de preparacion; compuestos intermediarios; composicion farmaceutica; y uso en la prevencion o el tratamiento de la enfermedad de alzheimer.
BR112017012930A2 (pt) derivados de imidazopiridazina como inibidores de pi3kbeta.
RU2016134903A (ru) Композиция для ускорения проникновения через кожу, препарат для трансдермального введения и препарат трансдермального пластыря